Does the media refer more to MLTX or TVTX?

In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Travere Therapeutics. MarketBeat recorded 20 mentions for MoonLake Immunotherapeutics and 16 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.09 beat MoonLake Immunotherapeutics' score of 0.91 indicating that Travere Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Travere Therapeutics 6 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CRSP or MLTX?

In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 20 mentions for MoonLake Immunotherapeutics and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.99 beat MoonLake Immunotherapeutics' score of 0.91 indicating that CRISPR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, DYN or MLTX?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.33 N/A MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A

Is DYN or MLTX more profitable?

Dyne Therapeutics' return on equity of -64.30% beat MoonLake Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -64.30% -50.33% MoonLake Immunotherapeutics N/A -93.09% -63.83%

Does the media prefer DYN or MLTX?

In the previous week, MoonLake Immunotherapeutics had 17 more articles in the media than Dyne Therapeutics. MarketBeat recorded 20 mentions for MoonLake Immunotherapeutics and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat MoonLake Immunotherapeutics' score of 0.91 indicating that Dyne Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MoonLake Immunotherapeutics 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, MLTX or CELC?

Celcuity is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MoonLake Immunotherapeutics N/A N/A -$227.32M -$3.84 N/A Celcuity N/A N/A -$177.04M -$3.90 N/A

Is MLTX or CELC more profitable?

MoonLake Immunotherapeutics' return on equity of -93.09% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets MoonLake Immunotherapeutics N/A -93.09% -63.83% Celcuity N/A -244.61% -50.22%

Does the media favor MLTX or CELC?

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Celcuity. MarketBeat recorded 20 mentions for MoonLake Immunotherapeutics and 17 mentions for Celcuity. MoonLake Immunotherapeutics' average media sentiment score of 0.91 beat Celcuity's score of 0.84 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 8 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

MoonLake Immunotherapeutics (MLTX) Competitors

$16.52 +0.02 (+0.09%)

As of 11:45 AM Eastern

Compare

MLTX vs. TVTX, CRSP, DYN, CELC, and ACAD

Should you buy MoonLake Immunotherapeutics stock or one of its competitors? MoonLake Immunotherapeutics's main competitors and comparable companies include Travere Therapeutics (TVTX), CRISPR Therapeutics (CRSP), Dyne Therapeutics (DYN), Celcuity (CELC), and ACADIA Pharmaceuticals (ACAD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Travere Therapeutics (NASDAQ:TVTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability.

Travere Therapeutics has higher revenue and earnings than MoonLake Immunotherapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Travere Therapeutics	$490.73M	11.79	-$25.55M	-$0.46	N/A

In the previous week, MoonLake Immunotherapeutics had 4 more articles in the media than Travere Therapeutics. MarketBeat recorded 20 mentions for MoonLake Immunotherapeutics and 16 mentions for Travere Therapeutics. Travere Therapeutics' average media sentiment score of 1.09 beat MoonLake Immunotherapeutics' score of 0.91 indicating that Travere Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Travere Therapeutics	6 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Travere Therapeutics' net margin of -7.35%. Travere Therapeutics' return on equity of -55.15% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-93.09%	-63.83%
Travere Therapeutics	-7.35%	-55.15%	-6.88%

MoonLake Immunotherapeutics currently has a consensus target price of $24.57, suggesting a potential upside of 48.89%. Travere Therapeutics has a consensus target price of $61.67, suggesting a potential upside of 0.51%. Given MoonLake Immunotherapeutics' higher probable upside, research analysts clearly believe MoonLake Immunotherapeutics is more favorable than Travere Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Travere Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69

93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 4.4% of Travere Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

MoonLake Immunotherapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Travere Therapeutics has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market.

Summary

Travere Therapeutics beats MoonLake Immunotherapeutics on 8 of the 14 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and media sentiment.

CRISPR Therapeutics has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

MoonLake Immunotherapeutics has a net margin of 0.00% compared to CRISPR Therapeutics' net margin of -3,368.72%. CRISPR Therapeutics' return on equity of -24.39% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-3,368.72%	-24.39%	-18.25%
MoonLake Immunotherapeutics	N/A	-93.09%	-63.83%

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. 5.2% of CRISPR Therapeutics shares are held by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CRISPR Therapeutics currently has a consensus price target of $68.06, suggesting a potential upside of 27.82%. MoonLake Immunotherapeutics has a consensus price target of $24.57, suggesting a potential upside of 48.89%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

MoonLake Immunotherapeutics has lower revenue, but higher earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,466.74	-$581.60M	-$4.76	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

In the previous week, MoonLake Immunotherapeutics had 12 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 20 mentions for MoonLake Immunotherapeutics and 8 mentions for CRISPR Therapeutics. CRISPR Therapeutics' average media sentiment score of 0.99 beat MoonLake Immunotherapeutics' score of 0.91 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MoonLake Immunotherapeutics beats CRISPR Therapeutics on 8 of the 15 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and MoonLake Immunotherapeutics (NASDAQ:MLTX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Dyne Therapeutics presently has a consensus target price of $34.42, indicating a potential upside of 34.97%. MoonLake Immunotherapeutics has a consensus target price of $24.57, indicating a potential upside of 48.89%. Given MoonLake Immunotherapeutics' higher possible upside, analysts plainly believe MoonLake Immunotherapeutics is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41

Dyne Therapeutics is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A

Dyne Therapeutics has a beta of 1.07, meaning that its stock price is 7% more volatile than the broader market. Comparatively, MoonLake Immunotherapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

Dyne Therapeutics' return on equity of -64.30% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
MoonLake Immunotherapeutics	N/A	-93.09%	-63.83%

In the previous week, MoonLake Immunotherapeutics had 17 more articles in the media than Dyne Therapeutics. MarketBeat recorded 20 mentions for MoonLake Immunotherapeutics and 3 mentions for Dyne Therapeutics. Dyne Therapeutics' average media sentiment score of 1.25 beat MoonLake Immunotherapeutics' score of 0.91 indicating that Dyne Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MoonLake Immunotherapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 10.4% of MoonLake Immunotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Dyne Therapeutics beats MoonLake Immunotherapeutics on 8 of the 13 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to Celcuity?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

In the previous week, MoonLake Immunotherapeutics had 3 more articles in the media than Celcuity. MarketBeat recorded 20 mentions for MoonLake Immunotherapeutics and 17 mentions for Celcuity. MoonLake Immunotherapeutics' average media sentiment score of 0.91 beat Celcuity's score of 0.84 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics' return on equity of -93.09% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-93.09%	-63.83%
Celcuity	N/A	-244.61%	-50.22%

MoonLake Immunotherapeutics currently has a consensus target price of $24.57, suggesting a potential upside of 48.89%. Celcuity has a consensus target price of $153.64, suggesting a potential upside of 66.04%. Given Celcuity's stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Celcuity	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.82

Celcuity is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A

MoonLake Immunotherapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, Celcuity has a beta of 0.2, meaning that its stock price is 80% less volatile than the broader market.

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 13.3% of Celcuity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

MoonLake Immunotherapeutics beats Celcuity on 7 of the 12 factors compared between the two stocks.

How does MoonLake Immunotherapeutics compare to ACADIA Pharmaceuticals?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, earnings, dividends, profitability, risk, valuation and analyst recommendations.

ACADIA Pharmaceuticals has higher revenue and earnings than MoonLake Immunotherapeutics. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
ACADIA Pharmaceuticals	$1.07B	4.53	$391M	$2.22	12.69

MoonLake Immunotherapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.81, meaning that its stock price is 19% less volatile than the broader market.

In the previous week, ACADIA Pharmaceuticals had 3 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 23 mentions for ACADIA Pharmaceuticals and 20 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.91 beat ACADIA Pharmaceuticals' score of 0.73 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	8 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	9 Very Positive mention(s)	4 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics presently has a consensus target price of $24.57, indicating a potential upside of 48.89%. ACADIA Pharmaceuticals has a consensus target price of $33.69, indicating a potential upside of 19.61%. Given MoonLake Immunotherapeutics' higher probable upside, equities analysts clearly believe MoonLake Immunotherapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
ACADIA Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.82

ACADIA Pharmaceuticals has a net margin of 33.42% compared to MoonLake Immunotherapeutics' net margin of 0.00%. ACADIA Pharmaceuticals' return on equity of 9.03% beat MoonLake Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-93.09%	-63.83%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

ACADIA Pharmaceuticals beats MoonLake Immunotherapeutics on 12 of the 15 factors compared between the two stocks.

Get MoonLake Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MLTX vs. The Competition

Export

Metric	MoonLake Immunotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.22B	$3.69B	$6.97B	$13.06B
Dividend Yield	N/A	3.76%	2.58%	10.72%
P/E Ratio	-4.30	10.36	269.56	25.27
Price / Sales	N/A	1,288.04	596.64	100.41
Price / Cash	N/A	103.01	70.53	50.75
Price / Book	3.86	17.39	13.00	6.30
Net Income	-$227.32M	-$13.32M	$3.45B	$347.83M
7 Day Performance	-9.56%	0.34%	0.57%	0.94%
1 Month Performance	-15.39%	0.13%	1.22%	0.90%
1 Year Performance	-69.91%	53.78%	66.67%	20.40%

MoonLake Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MLTX MoonLake Immunotherapeutics	3.5303 of 5 stars	$16.50 +0.0%	$24.57 +48.9%	-70.4%	$1.22B	N/A	N/A	2	Earnings Report Analyst Forecast
TVTX Travere Therapeutics	1.7733 of 5 stars	$54.91 -0.1%	$52.58 -4.2%	+240.3%	$5.11B	$490.73M	N/A	460	Positive News Analyst Revision
CRSP CRISPR Therapeutics	3.6203 of 5 stars	$51.91 +4.7%	$67.78 +30.6%	-6.7%	$5.01B	$3.51M	N/A	460
DYN Dyne Therapeutics	3.7459 of 5 stars	$25.78 +2.1%	$34.42 +33.5%	+112.1%	$4.80B	N/A	N/A	100	Gap Up
CELC Celcuity	3.6774 of 5 stars	$91.68 +4.5%	$155.18 +69.3%	+65.4%	$4.47B	N/A	N/A	40	Trending News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MLTX) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. TVTX, CRSP, DYN, CELC, and ACAD

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Dyne Therapeutics?

Summary

How does MoonLake Immunotherapeutics compare to Celcuity?

Summary

How does MoonLake Immunotherapeutics compare to ACADIA Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MoonLake Immunotherapeutics (MLTX) Competitors

MLTX vs. TVTX, CRSP, DYN, CELC, and ACAD

How does MoonLake Immunotherapeutics compare to Travere Therapeutics?

Which has better earnings & valuation, MLTX or TVTX?

Does the media refer more to MLTX or TVTX?

Is MLTX or TVTX more profitable?

Do analysts prefer MLTX or TVTX?

Do institutionals & insiders hold more shares of MLTX or TVTX?

Which has more risk & volatility, MLTX or TVTX?

Summary

How does MoonLake Immunotherapeutics compare to CRISPR Therapeutics?

Which has more volatility & risk, CRSP or MLTX?

Is CRSP or MLTX more profitable?

Do institutionals & insiders hold more shares of CRSP or MLTX?

Do analysts recommend CRSP or MLTX?

Which has preferable earnings & valuation, CRSP or MLTX?

Does the media refer more to CRSP or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Dyne Therapeutics?

Do analysts recommend DYN or MLTX?

Which has preferable earnings & valuation, DYN or MLTX?

Which has more risk and volatility, DYN or MLTX?

Is DYN or MLTX more profitable?

Does the media prefer DYN or MLTX?

Do institutionals & insiders believe in DYN or MLTX?

Summary

How does MoonLake Immunotherapeutics compare to Celcuity?

Does the media favor MLTX or CELC?

Is MLTX or CELC more profitable?

Do analysts prefer MLTX or CELC?

Which has higher valuation & earnings, MLTX or CELC?

Which has more volatility & risk, MLTX or CELC?

Do institutionals & insiders hold more shares of MLTX or CELC?

Summary

How does MoonLake Immunotherapeutics compare to ACADIA Pharmaceuticals?

Which has better valuation & earnings, MLTX or ACAD?

Which has more volatility and risk, MLTX or ACAD?

Does the media prefer MLTX or ACAD?

Do analysts prefer MLTX or ACAD?

Is MLTX or ACAD more profitable?

Do insiders and institutionals have more ownership in MLTX or ACAD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLTX vs. The Competition

MoonLake Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools